EP Patent

EP3363798A1 — Amorphous form of telotristat etiprate

Assigned to Esteve Quimica SA · Expires 2018-08-22 · 8y expired

What this patent protects

The present invention relates to amorphous forms of telotristat etiprate, to processes for preparing them, to pharmaceutical compositions comprising them, and to their medical use for the treatment of serotonin-mediated diseases or disorders.

USPTO Abstract

The present invention relates to amorphous forms of telotristat etiprate, to processes for preparing them, to pharmaceutical compositions comprising them, and to their medical use for the treatment of serotonin-mediated diseases or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3363798A1
Jurisdiction
EP
Classification
—
Expires
2018-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Esteve Quimica SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.